rav@pharmasentinel.com © 2021 Proprietary & Confidential – medsii®

Predicting & Preventing

Future Health Problems

®

- Predicting & Preventing Health Problems

© 2021 Proprietary & Confidential – medsii®

rav@pharmasentinel.com Video Introduction

- Google & Social Media: unverified, conflicting & dubious- WebMD & specialized sites difficult to read & understand

Self Diagnosis Information Overload

- Multiple sources needed for News & Info, including co-morbidities

- Patient information leaflets unreadable

Fragmented Information Sources

- Only few people can understand health information they need

- People from lower socio-economic groups have poorer health outcomes

Health Disparities

© 2021 Proprietary & Confidential – medsii®

a

The Problem

46% of UK on at least 1repeat prescription*

inc. 60% of women in 50s

1 in 3 of the world have at least 2 Chronic

Conditions*

1/3 1.3Bn29M

© 2021 Proprietary & Confidential – medsii®

1.3 bn Medicines prescribed in 2019 just

in the UK*

Size of the Problem

* Source: NHS Repeat Prescriptions Report * Source: NHS Repeat Prescriptions Report* Source: US National Institutes of Health

- We scan, monitor and select the latest health & medicines information from trusted sources

- We curate and publish them in a succinct, readable & comprehensible format

Comprehensive Health Information

- Mobile-first, award-winning User Experience- Deliver timely, actionable news & information to any

device and anywhere

Patient-Centric, Timely & Free

- Targeted, relevant and personalized health & medicines news pushed to each user

- Track conditions as well as co-morbidities

AI-driven Proactive Delivery

The Solution

© 2021 Proprietary & Confidential – medsii®

Live now or visit medsii.com

The Product

© 2021 Proprietary & Confidential – medsii®

Push App Alerts

AI Tailored News

Patient Spprt Grps

Trusted Sources

Google WebMD NHS UK Regulatoryauthorities

Patients Like Me

? 1

? 2

1 Google alerts allow users to signup for different types of alerts; however alerts are not easily customizable by users for the manifold variations in medicines & medical conditions2 Google search promotes advertisements to the top of results, thereby prioritizing listings of commercial companies and their products/services rather than relevance © 2021 Proprietary & Confidential – medsii®

Mobile First

Global Sources

Competitor Analysis

• 3k webapp users on medsii.com

• 1.2k webapp users in last 30 days

• Minimal paid promotions to-date - $50 a day

• UK highest butUSA starts July

• 100+ countries

• 20k native app downloads since Oct 2020 launch• 31k app user interactions in the last 30 days

Click to See Video“I'm much impressed by the app. It will be key in my training towards writing my license exams”

Alfred Kwama, Trainee Pharmacist in Ghana, Africa

Traction & Feedback

© 2021 Proprietary & Confidential – medsii®

197 million with at least 1

chronic condition

150 million Smartphone

users 21 million

© 2021 Proprietary & Confidential – medsii®

Market Opportunity

- Initial markets: UK, US & Italy- Also targeting English speakers in: India, Pakistan, Philippines, Nigeria

Target Addressable

Market Service Addressable

Market

Service Obtainable

Market

Premium Subscriptions

Ads &

sponsored posts

© 2021 Proprietary & Confidential – medsii®

Revenue Model – B2C

$5/month$50/year

Connect with Professionals

3rd Party Writers & Creators- Doctors & Pharmacists- Academics & Scientists- Medical Lawyers

medsii premium content- Allergies- Drug interactions- Analytics Dashboard

Native Ads- Promoted posts- Manual placement- Real Time Bidding

Licensed Data

Services

White Label

Services

© 2021 Proprietary & Confidential – medsii®

Revenue Model – B2B

Data-as-a-service for:

- Pharma

- Biotech

- Insurance

- Financial Analysts

Distribution channel for:

- Retailers

- Pharmacies

- Health Insurers

- Companies

®

Personalized Walmart Offers

Pharmacist Tele-consultations

Follow Topics, Conditions

& Medicines

Report Side Effects here

Walmart Diet Promo here

Click to Like, Save & Share

Keep Updated with

AI Push Notifications

© 2021 Proprietary & Confidential – medsii®

White Label – Walmart Use Case

Q3 2020 Q1 2021 Q2 2021 Q4 2021 Q1 2022

AI recommender live

medsii White Label Launch

2021 Webby Honoree Award in the Health & Wellness Category

In-app programmatic Ads

Closed Pre-seed

Round $300k

Commenced Seed Round

$1.1M

Launched iOS and Android apps and Medsii platform

USA Market Launch

Q3 2022

Allergy Data Integrated

AI Development

Continues

Commence Series A Round

Q4 2020

Launched medsii.com webapp

HIPAA Compliance

Medsii Creators Launch

Italy Launch

medsii Premium Service LaunchSOC2 & ISO27001

Compliance

BUILD

SCALE

Roadmap

Q3 2021 Q2 2022

© 2021 Proprietary & Confidential – medsii®

© 2021 Proprietary & Confidential – medsii®

Potential Outcomes

Best-case scenarioMarket leader

B2C & B2B

$1B Valuation

Realistic ScenarioB2C PenetrationB2B Revenues

$100M Valuation

Worst Case ScenarioImprove Health OutcomeReduce Health Disparities

We Help People

Salaries23%

Marketing 28%

Technology28%

Content production 19%

Flex 2%

Seed Capital of $1.1m Will get us to

© 2021 Proprietary & Confidential – medsii®

The Ask

S/EIS Approved

-

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

-$5,000,000

$0

$5,000,000

$10,000,000

$15,000,000

$20,000,000

$25,000,000

21/22 22/23 23/24 24/25

Total B2C Revenues Cost Profit Registered users

Nasir Hussain PhD (CSO)25+ years of pharma experience (Eli Lilly, Gilead) including 5 years at the MHRA (UK medicines regulator) & representing the MHRA at the European Medicines Agency

UK registered pharmacist with deep knowledgeof drug development & regulatory requirements

Has been involved as a founder & employee in 5 early-stage start-ups

Rav Roberts MBA (CEO)A track record in the USA & UK of successfully leading diverse teams, delivering complex, global digital products & systems (Accenture, Diageo)

Co-founded 2 startups (1 in San Francisco)

Rav, a type 2 diabetic, is passionate about helpingpeople understand their medicines & conditions

Deep understanding of launching digital platforms, paid, earned & owned digital marketing channels, global digital & data governance + GDPR compliance

Paolo Ursino MBA (CTO)25+ years experience in a wide range of tech, including cellular comms, IoT, B2B and B2C cloud platforms, web and mobile apps

Worked for large corporates, e.g. Samsung & Broadcom, as well as co-founding two start-ups

Paolo is passionate about technology with MSc in electronical engineering from the University of Bologna, Italy

© 2021 Proprietary & Confidential – medsii®

The Team

Dr. Annabelle PainterAnnabelle is a NHS Doctor working in med-tech & studied medicine at the University of Oxford

Co-founder of the Digital Doctors Network &member of the Digital Health Council at the UK’sRoyal Society of Medicine

Previously an AI Clinician at Babylon Health

He has an Executive MBA from Cass Business School, & substantial experience advising international businesses on executive compensation, employee incentives, M&A, IPOs, private equity, advisory corporate, corporate governance, employment law & successfully building teams of lawyers

Brenda King MBEBrenda was awarded a MBE by the Queen in 2004 awarded for services to the UK’s BAME communities as CEO of her Black African Caribbean charity

Working with Brenda on an app version to support the UK Black community disproportionally impacted by Covid-19

Brenda has a BSc in Statistics & Computing (UCL ) & MSc Management Science (Warwick)

Dr. Robert Adams MD, MBABob, our US Brand Ambassador advising on ourUSA market entry, is a retired, distinguished USArmy Colonel & former US Navy SEAL

Bob founded & practiced in his full-service clinic Knightdale Family Medicine

Bob is on a charity Board serving at-risk male & female US veterans www.vlcnc.org & on the Board of the Institute for Medical Research US Veterans Administration www.imr.org

Jeremy GloverJeremy Glover acts as our In-house Legal Counsel

© 2021 Proprietary & Confidential – medsii®

Advisors

▪ 10% of profits to Patient Support

Groups chosen by users

▪ 1,713 votes cast by users

CSR is central to our strategy

Top 12 Charities Chosen

Allergy UK

Diabetes UK

MIND

Action on Pain

Bowel Cancer UK

Alzheimer’s Soc.

Blood Pressure UK

Anxiety Care

Heart UK

British Lung Fndn.

Breast Cancer Now

Addiction Today

209

199

103

96

77

71

57

56

55

54

53

52

© 2021 Proprietary & Confidential – medsii®

Corporate Social Responsibility @ Pharma Sentinel

Launched October 2020

Raising $1.1m in Seed funding

S/EIS Advance Assurance Approved

®

© 2021 Proprietary & Confidential – medsii®

Thank you

medsii.com

rav@pharmasentinel.com

Video Introduction

Business Model: B2C 1st & 3rd Party Data Drives B2B

Pharma & BiotechCompetitor medicines market intelligence + side

effects of marketed medicines with augmented

data sets

InsurancePatient co-pay modelling & actuarial

risk & life tables assessment

White Label ServiceHealth Insurers, pharmacy retailers etc. offer a

white label solution to their customers / employees

Doctors, Pharmacists &

Healthcare ProfessionalsPharmacists, HCPs, scientists and students

receiving up-to-date medicines alerts

FMCG Hygiene, CosmeticsConsumer behavior, competitor information and

brand & product protection

Data Platform

machine learning

medsii 1st Party Data

UK - 29 mil medicine takers

(58 MILLION smartphone users)

USA - 131 mil medicine takers

(251 MILLION smartphone users)

INDIA - 463 mil medicine takers

(375 million smartphone users)

LATAM - 200 mil medicine takers

(250 million smartphone users)

3rd Party Data

Side Effects

Diet

Pollution

Health Records

ITA - 22 mil medicine takers

(53 MILLION smartphone users)

© 2021 Proprietary & Confidential – medsii®

Total Addressable Market (UK Only)

Pharma Sentinel UK Target Market 23 million

(Age between 20 and 79 with at least one chronic condition)

UK Total Addressable Market

29 million people

34,711,380 32% of women in their 20s

(1,380,214)16% of men in their 20s

(702,563)

38% of women in their 30s

(1,595,397)28% of men in their 30s

(1,162,527)

29,106,997 45% of women in their 40s

(2,065,143)39% of men in their 40s

(1,744,802)

61% of women in their 50s

(2,562,536)53% Of men in their 50s

(2,173,006)

16,029,153

13,007,844

females

males

29,106,997 on at least one repeat

prescription (46% of UK population),

49% of all females & 42% of males.

Data Sources: ONS, NHS (2017)© 2021 Proprietary & Confidential – medsii®

UK Consumers TAM (Breakdown)

Aged between 20 and 79 with at

least one chronic condition

148,314

2,562,536

1,744,802

2,065,132

1,162,527

1,595,397

702,563

1,380,214

793,908

862,490

764,145

624,351

Female 90+ 373,378

Male 80-89 959,904

Female 80-89 1,424,298

Male 70-79

Female 70-79

2,006,915

2,314,878

Male 60-69 2,621,761

Female 60-69 2,826,480

Male 50-59 2,173,006

Male 90+

Female 50-59

Male 40-49

Female 40-49

Male 30-39

Female 30-39

Male 20-29

Female 20-29

Male 10-19

Female 10-19

Male 0-9

Female 0-9

23,156,210

© 2021 Proprietary & Confidential – medsii®

Our Mission

To Democratize Medicines & Health Information to

Proactively Improve Patient Well-being & Health Outcomes

© 2021 Proprietary & Confidential – medsii®

medsii is a highly scalable, secure & GDPR compliant award-winning

UK HealthTech startup with global ambitions, addressing the rising

demand for trusted medicines & medical conditions news &

information.

- Our technology helps each user to lead a safer life by using AI to

deliver free, trusted, comprehensible & highly customized

medicines & medical conditions news & information.

- Users can follow & register for push-alert news on heart disease,

arthritis neurological disorders, diabetes, sports injuries & more.

- medsii will soon be launching a ‘creator’ service, enabling doctors,

pharmacists, health academics & scientists to monetise their

knowledge, via subscriptions on our platform.

Live now or visit medsii.com

© 2021 Proprietary & Confidential – medsii®

Appendix: Product Screens

DISCLAIMER

This documentis issuedby Pharma SentinelLimited(theCompany), owner of the registered trademark medsii,a companyregisteredin England

and Wales withcompanynumber 12090356.

This documentis notdesignedas a promotionand has notbeenapprovedby an authorisedpersonwithin themeaning oftheFinancialServices& MarketsAct

2000.Youareadvisedtoexercisecautionand notrelyon itforthepurposeofany investmentactivity.

Theinformationcontained in this documentandtheopinions expressedhereinareforinformationpurposesand notforanyotherpurpose.This documenthas

not been independently verified and no representation is made, nor any warranty given, as to the accuracy or completeness of any information or the

reasonableness ofany statementsofopinionorbeliefor theachievabilityofany forecastsorprojectionscontainedwithintheinformation. Itdoes notform

partofan offeror invitationtopurchaseorsubscribeforsecuritiesand no reliancecan beplacedon itortheinformation itcontains.

No partofthis presentationmay be reproducedby anymeans whethergraphically,electronically,mechanicallyorotherwise,withoutthepermission ofthe

Company.

No liabilityin respectofthecontentsofthis presentationis acceptedby theCompanyoranyassociatedcompany.

© 2021 Proprietary & Confidential – medsii®